Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
KDA Group Inc. stock logo
KDA
KDA Group
C$0.41
-3.6%
C$0.44
C$0.03
C$0.66
C$70.96M1.15106,767 shs64,160 shs
MNX
Manitex Capital
C$0.17
-19.0%
C$0.20
C$0.17
C$0.58
C$2.15M0.475,417 shs5,000 shs
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
$22.92
+0.2%
$23.68
$21.58
$31.49
$406.17M0.9985,003 shs108,842 shs
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
$13.88
+0.9%
$13.30
$11.36
$18.01
N/AN/A13,163 shs2,520 shs
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
KDA Group Inc. stock logo
KDA
KDA Group
+9.09%+3.70%-6.67%+55.56%+366.67%
MNX
Manitex Capital
0.00%0.00%-19.05%-26.09%-69.09%
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
-8.63%-0.26%-2.26%-19.66%-12.30%
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
+2.86%+8.74%+5.28%+7.89%-19.12%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
KDA Group Inc. stock logo
KDA
KDA Group
N/AN/AN/AN/AN/AN/AN/AN/A
MNX
Manitex Capital
N/AN/AN/AN/AN/AN/AN/AN/A
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
4.0256 of 5 stars
3.32.01.70.01.62.53.8
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
KDA Group Inc. stock logo
KDA
KDA Group
N/AN/AN/AN/A
MNX
Manitex Capital
N/AN/AN/AN/A
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
2.50
Moderate Buy$30.5033.07% Upside
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
N/AN/AN/AN/A

Current Analyst Ratings

Latest UDG, PGC, KDA, MNX, and SHTDY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/24/2024
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Neutral
4/5/2024
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
Keefe, Bruyette & Woods
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$33.50 ➝ $30.50
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
KDA Group Inc. stock logo
KDA
KDA Group
C$28.71M2.47C$0.08 per share5.00C$0.09 per share4.50
MNX
Manitex Capital
C$-1.04M-2.06C$0.06 per share2.79C$0.76 per share0.22
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
$225.83M1.80$3.48 per share6.59$32.76 per share0.70
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
KDA Group Inc. stock logo
KDA
KDA Group
-C$1.73MN/AN/AN/A15,418.62%N/A-11.42%7/6/2024 (Estimated)
MNX
Manitex Capital
-C$2.05MC$0.072.43N/AN/A9.26%-2.08%N/A
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
$48.85M$2.1810.517.96N/A10.11%7.27%0.64%7/23/2024 (Estimated)
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
N/A$4.992.78N/AN/AN/AN/AN/A

Latest UDG, PGC, KDA, MNX, and SHTDY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
1/25/2024Q4 2023
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
$0.56$0.50-$0.06$0.52$54.91 million$54.27 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
KDA Group Inc. stock logo
KDA
KDA Group
N/AN/AN/AN/AN/A
MNX
Manitex Capital
N/AN/AN/AN/AN/A
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
$0.200.87%N/A9.17%N/A
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
N/AN/AN/AN/AN/A

Latest UDG, PGC, KDA, MNX, and SHTDY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/28/2024
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
quarterly$0.050.9%5/8/20245/9/20245/23/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
KDA Group Inc. stock logo
KDA
KDA Group
16.77
1.96
0.35
MNX
Manitex Capital
3.56
1.35
2.52
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
0.23
0.98
0.98
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
KDA Group Inc. stock logo
KDA
KDA Group
N/A
MNX
Manitex Capital
N/A
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
72.75%
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
N/A

Insider Ownership

CompanyInsider Ownership
KDA Group Inc. stock logo
KDA
KDA Group
25.51%
MNX
Manitex Capital
61.15%
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
7.63%
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
KDA Group Inc. stock logo
KDA
KDA Group
N/A175.22 millionN/ANot Optionable
MNX
Manitex Capital
N/A12.66 millionN/ANot Optionable
Peapack-Gladstone Financial Co. stock logo
PGC
Peapack-Gladstone Financial
52117.75 million16.40 millionOptionable
Sinopharm Group Co. Ltd. stock logo
SHTDY
Sinopharm Group
115,959N/AN/ANot Optionable

UDG, PGC, KDA, MNX, and SHTDY Headlines

SourceHeadline
Short Interest in Sinopharm Group Co. Ltd. (OTCMKTS:SHTDY) Expands By 33.5%Short Interest in Sinopharm Group Co. Ltd. (OTCMKTS:SHTDY) Expands By 33.5%
americanbankingnews.com - April 15 at 4:56 AM
Sinopharm Group Co LtdSinopharm Group Co Ltd
morningstar.com - April 13 at 12:49 PM
Study: Pfizer vaccine showed strongest immune response in MoroccoStudy: Pfizer vaccine showed strongest immune response in Morocco
msn.com - April 8 at 11:43 AM
Buy Rating for Sinopharm Group Co. Amidst Market Consolidation and Efficiency GainsBuy Rating for Sinopharm Group Co. Amidst Market Consolidation and Efficiency Gains
markets.businessinsider.com - March 27 at 5:36 PM
World’s journalists visit industrial zones in BeijingWorld’s journalists visit industrial zones in Beijing
tehrantimes.com - March 17 at 12:52 AM
Xinhua Silk Road: Electric tricycles made in E. Chinas Rizhao popular abroadXinhua Silk Road: Electric tricycles made in E. China's Rizhao popular abroad
tmcnet.com - March 15 at 6:27 PM
Sinopharm Group Co. - Depositary Receipt () (SHTDY) Price Target Increased by 11.16% to 15.28Sinopharm Group Co. - Depositary Receipt () (SHTDY) Price Target Increased by 11.16% to 15.28
msn.com - February 25 at 12:07 AM
Hong Kong Stocks: Sinopharm to Buyout China-TCM for HK$23.2BHong Kong Stocks: Sinopharm to Buyout China-TCM for HK$23.2B
msn.com - February 22 at 2:53 PM
Pharma Wholesale and Distribution market is projected to grow at a CAGR of 8.7% by 2034: VisiongainPharma Wholesale and Distribution market is projected to grow at a CAGR of 8.7% by 2034: Visiongain
uk.finance.yahoo.com - February 21 at 2:12 PM
Chorionic Gonadotrophin for Injection Market Spectrum: Applications, Trends, And Key Players In The Chorionic Gonadotrophin for Injection MarketChorionic Gonadotrophin for Injection Market Spectrum: Applications, Trends, And Key Players In The Chorionic Gonadotrophin for Injection Market
opprairie.com - February 21 at 2:12 PM
Sinopharm Group Co Ltd ADRSinopharm Group Co Ltd ADR
thestreet.com - February 19 at 1:13 PM
Navigating Through The Penicillin G Potassium First Crystals Market LandscapeNavigating Through The Penicillin G Potassium First Crystals Market Landscape
opprairie.com - February 18 at 8:39 PM
Clonazepam API Market Booming With Top Key Players Executing Different Strategies And PlansClonazepam API Market Booming With Top Key Players Executing Different Strategies And Plans
opprairie.com - January 30 at 1:06 PM
Sinopharm Group Co Ltd ADR SHTDYSinopharm Group Co Ltd ADR SHTDY
morningstar.com - November 7 at 7:27 AM
Local transmission of monkeypox virus in Beijing has been significantly suppressed: Chinese CDCLocal transmission of monkeypox virus in Beijing has been significantly suppressed: Chinese CDC
globaltimes.cn - October 15 at 2:02 PM
Sinopharms mRNA vaccines can provide effective protection against monkeypox: studySinopharm's mRNA vaccines can provide effective protection against monkeypox: study
globaltimes.cn - September 25 at 1:29 PM
Hong Kong stocks slide amid China property default risk while Sinopharm slides on index debut, LOccitane crashesHong Kong stocks slide amid China property default risk while Sinopharm slides on index debut, L'Occitane crashes
finance.yahoo.com - September 5 at 7:08 AM
Cefaclor Capsules Market to Expand with Strong Development by 2029 – China Union Chempharma, Sinopharm, AGP Limited, Carlsbad TechnologyCefaclor Capsules Market to Expand with Strong Development by 2029 – China Union Chempharma, Sinopharm, AGP Limited, Carlsbad Technology
puyalluppost.com - June 28 at 10:05 AM
WHO recommends updating COVID shots to add XBB.1 variantsWHO recommends updating COVID shots to add XBB.1 variants
msn.com - May 18 at 3:28 PM
Endurance RP: Excellent Positive Results from Phase 3 Randomised Clinical Trial of Fortacin(TM)/Senstend(TM) in ChinaEndurance RP: Excellent Positive Results from Phase 3 Randomised Clinical Trial of Fortacin(TM)/Senstend(TM) in China
asiaone.com - April 17 at 5:26 PM
Chlorpheniramine Maleate Market Outlook and Forecast till 2031Chlorpheniramine Maleate Market Outlook and Forecast till 2031
marketwatch.com - March 30 at 10:21 AM
Sinopharm’s Earnings Slightly Better Than ExpectedSinopharm’s Earnings Slightly Better Than Expected
morningstar.com - March 29 at 7:25 PM
2023-2029 Gold(III) Bromide (AuBr3) Market Size and Industrial Overview with Region Footprint | Latest Report by Absolute Reports2023-2029 Gold(III) Bromide (AuBr3) Market Size and Industrial Overview with Region Footprint | Latest Report by Absolute Reports
marketwatch.com - March 29 at 4:22 AM
7-Aminocephalosporanic Acid (7-ACA) Market Outlook By 20317-Aminocephalosporanic Acid (7-ACA) Market Outlook By 2031
marketwatch.com - March 28 at 10:26 PM

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

KDA Group logo

KDA Group

CVE:KDA
KDA Group Inc., together with its subsidiaries, provides solutions and services to pharmacies and pharmaceutical companies in Canada. The company operates through three segments: Pharmacy Services, Pharmaceutical Solutions, and Technology. It provides pharmacy staff replacement services, professional and continued medical training services, pharmacy re-engineering services, and pharmaceutical training services. The company also offers PREDICTIVE e-Prescriber software for assisting doctors; and KRx, a cloud-based solution that analyzes each user's prescription pattern and displays the appropriate expected medication. The company was formerly known as AlliancePharma Inc. and changed its name to KDA Group Inc. in February 2017. KDA Group Inc. was founded in 2009 and is headquartered in Thetford Mines, Canada.

Manitex Capital

CVE:MNX
Manitex Capital Inc. focuses on acquiring interests in life sciences, cleantech, and sustainable products/technologies companies. It also holds a portfolio of marketable securities. Manitex Capital Inc. is headquartered in Kirkland, Canada.
Peapack-Gladstone Financial logo

Peapack-Gladstone Financial

NASDAQ:PGC
Peapack-Gladstone Financial Corporation operates as the bank holding company for Peapack-Gladstone Bank that provides private banking and wealth management services in the United States. The company operates in two segments, Banking and Peapack Private. It offers checking and savings accounts, money market and interest-bearing checking accounts, certificates of deposit, and individual retirement accounts. The company also provides working capital lines of credit, term loans for fixed asset acquisitions, commercial mortgages, multi-family mortgages, and other forms of asset-based financing services; and residential mortgages, home equity lines of credit, and other second mortgage loans. In addition, it offers corporate and industrial (C&I) and equipment finance, commercial real estate, multifamily, residential, and consumer lending activities; treasury management services; C&I advisory services; escrow management; deposit generation; investment management services; personal trust services, including services as executor, trustee, administrator, custodian, and guardian; and other financial planning, tax preparation, and advisory services. Further, the company provides telephone and Internet banking, merchant credit card, and customer support sales services. Its private banking clients include businesses, non-profits, and consumers; wealth management clients comprise individuals, families, foundations, endowments, trusts, and estates; and commercial loan clients include business owners, professionals, retailers, contractors, and real estate investors. The company operates its private banking locations in Bedminster, Morristown, Princeton, and Teaneck, New Jersey; and branches in Somerset, Morris, Hunterdon, and Union counties, as well as operates automated teller machines. Peapack-Gladstone Financial Corporation was founded in 1921 and is headquartered in Bedminster, New Jersey.
Sinopharm Group logo

Sinopharm Group

OTCMKTS:SHTDY
Sinopharm Group Co. Ltd., together with its subsidiaries, engages in the wholesale and retail of pharmaceutical and medical devices and healthcare products in the People's Republic of China. The company operates through four segments: Pharmaceutical Distribution, Medical Devices, Retail Pharmacy, and Other Business. The Pharmaceutical Distribution segment distributes pharmaceutical products to hospitals, other distributors, retail pharmacy stores, and clinics. This segment also offers distribution, logistics, and other value-added services for domestic and international pharmaceutical and healthcare products manufacturers, and other suppliers. The Medical Devices segment distributes medical devices. The Retail Pharmacy segment operates and franchises a network of retail drug stores. The Other Business segment engages in the production and sale of pharmaceutical products, chemical reagents, and laboratory supplies. The company also rents and manages properties; distributes medical instruments, Chinese herbal medicines, antibiotics, and biological products; and offers information technology development and medicine consultation, investment, goods and technology import and export, business consultation, health consultation, medical consulting, market information consulting and investigation, and convention and exhibition services. In addition, it manages medical project investment, consulting, and technology training activities. The company was founded in 2003 and is headquartered in Shanghai, the People's Republic of China. Sinopharm Group Co. Ltd. operates as a subsidiary of Sinopharm Industrial Investment Co., Ltd.